2018). Of all stroke events, ischaemic stroke (caused by decreased blood flow to the brain) accounts for approximately 87% in nature. The standard of care for clinical management of acute ischaemic stroke is intervention with intravenous thrombolysis via the recombinant tissue plasminogen activator (r-tPA). However, r-tPA therapy is less than ideal due to its the narrow treatment window, contraindications and complications, only 1–5% of patients currently receive tPA treatment (Aiyagari et al. 2004). The gene discussed is PLAT; the disease is Stroke.